TM London Day One
Wednesday, 6th December 2017
14.10 | Role of Genetically Engineered Mouse Models in Drug Discovery
Elizabeth Hardaker did her PhD and post doc in respiratory diseases at the National Heart and Lung Institute (NHLI) Imperial college. After this Elizabeth moved to Novartis Institute for Biomedical Research in the Respiratory disease area. Within this job role she developed a wide variety of in vivo models to investigate immune stimulatory agents that would enhance clearance of bacterial and viral infection. Subsequently Elizabeth moved to Evotec as a group leader where amongst other roles she was biology lead for an immune oncology project. Elizabeth is now a Team Leader at Astra Zeneca within the oncology in vivo team. As part of this role Elizabeth supports the strategy to introduce and characterise models to enable the group to actively support immune targeting therapies.